Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control
Posted inDiabetes & Endocrinology Internal Medicine news

Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control

This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic role of GIP in metabolic disease management.
Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
Posted inDiabetes & Endocrinology Internal Medicine news

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first evidence of successful immune intervention in the earliest stage of the disease.
Substituting Water for Artificially Sweetened Beverages Fails to Improve Glycemic Control in Type 2 Diabetes: Results from the SODAS Trial
Posted inDiabetes & Endocrinology Internal Medicine news

Substituting Water for Artificially Sweetened Beverages Fails to Improve Glycemic Control in Type 2 Diabetes: Results from the SODAS Trial

The Study of Drinks with Artificial Sweeteners (SODAS) randomized trial reveals that replacing habitual artificially sweetened beverages with water does not improve HbA1c levels in patients with type 2 diabetes, with the water group surprisingly showing higher HbA1c levels than the beverage group.
Behavioral Science-Integrated EHR Prompts Significantly Increase Deprescribing Rates for Older Adults: A Randomized Clinical Trial
Posted inFamily Medicine & Nutrition Internal Medicine news

Behavioral Science-Integrated EHR Prompts Significantly Increase Deprescribing Rates for Older Adults: A Randomized Clinical Trial

This randomized clinical trial demonstrates that EHR-based behavioral interventions, such as precommitment and boostering prompts, significantly improve deprescribing rates for potentially inappropriate medications in older adults, providing a scalable strategy to mitigate polypharmacy risks in primary care.
Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
Posted inGastroenterology Internal Medicine news

Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice

The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasize the need for sham-controlled evidence in interventional gastroenterology.